FDA and EMA Accept Regulatory Submission for Pfizer ’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata
Filings based on clinical data demonstrating significant scalp hair regrowth versus placebo
NEW YORK--(BUSINESS WIRE) September 09, 2022 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Alopecia | Alopecia Areata | Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications | Pfizer